|
Kosan Biosciences Incorporated (Nasdaq: KOSN - News)
today announced that the U.S. Food and Drug Administration has granted its
anticancer compound 17-allylamino-17-demethoxy- geldanamycin, or 17-AAG, an
analog of the polyketide geldanamycin, orphan drug status for the treatment of
Chronic Myelogenous Leukemia (CML). 17-AAG is being evaluated for the treatment
of multiple cancer indications in Phase II, Phase I, and Phase Ib clinical
trials, including a Phase Ib trial with Gleevec(TM) as a combination therapy in
CML.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [EMAIL PROTECTED] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML
Yahoo! Groups Links
|
